Targeting Histone 3 Variants Epigenetic Landscape and Inhibitory Immune Checkpoints: An Option for Paediatric Brain Tumours Therapy


Дәйексөз келтіру

Толық мәтін

Аннотация

Despite little progress in survival rates with regular therapies, which do not provide complete care for curing pediatric brain tumors (PBTs), there is an urgent need for novel strategies to overcome the toxic effects of conventional therapies to treat PBTs. The co-inhibitory immune checkpoint molecules, e.g., CTLA-4, PD-1/PD-L1, etc., and epigenetic alterations in histone variants, e.g., H3K27me3 that help in immune evasion at tumor microenvironment have not gained much attention in PBTs treatment. However, key epigenetic mechanistic alterations, such as acetylation, methylation, phosphorylation, sumoylation, poly (ADP)-ribosylation, and ubiquitination in histone protein, are greatly acknowledged. The crucial checkpoints in pediatric brain tumors are cytotoxic T lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PDL1), OX-2 membrane glycoprotein (CD200), and indoleamine 2,3-dioxygenase (IDO). This review covers the state of knowledge on the role of multiple co-inhibitory immunological checkpoint proteins and histone epigenetic alterations in different cancers. We further discuss the processes behind these checkpoints, cell signalling, the current scenario of clinical and preclinical research and potential futuristic opportunities for immunotherapies in the treatment of pediatric brain tumors. Conclusively, this article further discusses the possibilities of these interventions to be used for better therapy options.

Авторлар туралы

Sarasa Meenakshi

Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research

Email: info@benthamscience.net

Krushna Maharana

Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research

Email: info@benthamscience.net

Lokesh Nama

Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research

Email: info@benthamscience.net

Udaya Kumar Vadla

Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research

Email: info@benthamscience.net

Sameer Dhingra

Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research

Email: info@benthamscience.net

Velayutham Ravichandiran

Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research

Email: info@benthamscience.net

Krishna Murti

Department of Pharmacy Practice, National Institute of Pharmaceutical Education and Research

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Nitesh Kumar

Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research

Хат алмасуға жауапты Автор.
Email: info@benthamscience.net

Әдебиет тізімі

  1. Dong, H.; Strome, S.E.; Salomao, D.R.; Tamura, H.; Hirano, F.; Flies, D.B.; Roche, P.C.; Lu, J.; Zhu, G.; Tamada, K.; Lennon, V.A.; Celis, E.; Chen, L. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat. Med., 2002, 8(8), 793-800. doi: 10.1038/nm730 PMID: 12091876
  2. Topalian, S.L.; Drake, C.G.; Pardoll, D.M. Immune checkpoint blockade: A common denominator approach to cancer therapy. Cancer Cell, 2015, 27(4), 450-461. doi: 10.1016/j.ccell.2015.03.001 PMID: 25858804
  3. Vignali, D.A.A.; Collison, L.W.; Workman, C.J. How regulatory T cells work. Nat. Rev. Immunol., 2008, 8(7), 523-532. doi: 10.1038/nri2343 PMID: 18566595
  4. Facciabene, A.; Motz, G.T.; Coukos, G. T-regulatory cells: key players in tumor immune escape and angiogenesis. Cancer Res., 2012, 72(9), 2162-2171. doi: 10.1158/0008-5472.CAN-11-3687 PMID: 22549946
  5. Baylin, S.B.; Esteller, M.; Rountree, M.R.; Bachman, K.E.; Schuebel, K. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum. Mol. Genet., 2001, 10(7), 687-692.
  6. Héninger, E.; Krueger, T.E.; Lang, J.M. Augmenting antitumor immune responses with epigenetic modifying agents. Front. Immunol., 2015, 6, 49.
  7. Feinberg, A.P.; Koldobskiy, M.A.; Göndör, A.J.N.R.G. Epigenetic modulators, modifiers and mediators in cancer aetiology and progression. Nat. Rev. Genet., 2016, 17(5), 284-299. doi: 10.1038/nrg.2016.13
  8. He, C.; Xu, J.; Zhang, J.; Xie, D.; Ye, H.; Xiao, Z. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Hum. Pathol., 2012, 43(9), 1425-1435. doi: 10.1016/j.humpath.2011.11.003
  9. Hayashi, A.; Yamauchi, N.; Shibahara, J.; Kimura, H.; Morikawa, T.; Ishikawa, S.; Nagae, G.; Nishi, A.; Sakamoto, Y.; Kokudo, N.; Aburatani, H.; Fukayama, M. Concurrent activation of acetylation and tri-methylation of H3K27 in a subset of hepatocellular carcinoma with aggressive behavior. PLoS One, 2014, 9(3), e91330. doi: 10.1371/journal.pone.0091330 PMID: 24614346
  10. Li, D. Zeng, ZJBR Epigenetic regulation of histone H3 in the process of hepatocellular tumorigenesis. Biosci. Rep., 2019, 39(8), BSR20191815. doi: 10.1042/BSR20191815
  11. Berger, S.L.; Kouzarides, T.; Shiekhattar, R.; Shilatifard, A. An operational definition of epigenetics. Genes Dev., 2009, 23(7), 781-783. doi: 10.1101/gad.1787609 PMID: 19339683
  12. Xu, G.L.; Bestor, T.H.; Bourc’his, D.; Hsieh, C.L.; Tommerup, N.; Bugge, M.; Hulten, M.; Qu, X.; Russo, J.J.; Viegas-Péquignot, E. Chromosome instability and immunodeficiency syndrome caused by mutations in a DNA methyltransferase gene. Nature, 1999, 402(6758), 187-191. doi: 10.1038/46052 PMID: 10647011
  13. Portela, A.; Esteller, M. Epigenetic modifications and human disease. Nat. Biotechnol., 2010, 28(10), 1057-1068. doi: 10.1038/nbt.1685 PMID: 20944598
  14. Baylin, S.B.; Ohm, J.E. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat. Rev. Cancer, 2006, 6(2), 107-116. doi: 10.1038/nrc1799 PMID: 16491070
  15. Suzuki, M.M.; Bird, A. DNA methylation landscapes: provocative insights from epigenomics. Nat. Rev. Genet., 2008, 9(6), 465-476. doi: 10.1038/nrg2341 PMID: 18463664
  16. Bird, A. DNA methylation patterns and epigenetic memory. Genes Dev., 2002, 16(1), 6-21. doi: 10.1101/gad.947102 PMID: 11782440
  17. Esteller, M. Epigenetic gene silencing in cancer: the DNA hypermethylome. Hum. Mol. Genet., 2007, 16(R1), R50-R59. doi: 10.1093/hmg/ddm018 PMID: 17613547
  18. Lopez-Serra, L.; Esteller, M. Proteins that bind methylated DNA and human cancer: reading the wrong words. Br. J. Cancer, 2008, 98(12), 1881-1885. doi: 10.1038/sj.bjc.6604374 PMID: 18542062
  19. Sharma, S.V.; Lee, D.Y.; Li, B.; Quinlan, M.P.; Takahashi, F.; Maheswaran, S.; McDermott, U.; Azizian, N.; Zou, L.; Fischbach, M.A.; Wong, K.K.; Brandstetter, K.; Wittner, B.; Ramaswamy, S.; Classon, M.; Settleman, J. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell, 2010, 141(1), 69-80. doi: 10.1016/j.cell.2010.02.027 PMID: 20371346
  20. Kelly, T.K.; De Carvalho, D.D.; Jones, P.A. Epigenetic modifications as therapeutic targets. Nat. Biotechnol., 2010, 28(10), 1069-1078. doi: 10.1038/nbt.1678 PMID: 20944599
  21. Stupp, R.; Hegi, M.E.; Mason, W.P.; van den Bent, M.J.; Taphoorn, M.J.B.; Janzer, R.C.; Ludwin, S.K.; Allgeier, A.; Fisher, B.; Belanger, K.; Hau, P.; Brandes, A.A.; Gijtenbeek, J.; Marosi, C.; Vecht, C.J.; Mokhtari, K.; Wesseling, P.; Villa, S.; Eisenhauer, E.; Gorlia, T.; Weller, M.; Lacombe, D.; Cairncross, J.G.; Mirimanoff, R.O. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol., 2009, 10(5), 459-466. doi: 10.1016/S1470-2045(09)70025-7 PMID: 19269895
  22. Broniscer, A.; Chintagumpala, M.; Fouladi, M.; Krasin, M.J.; Kocak, M.; Bowers, D.C.; Iacono, L.C.; Merchant, T.E.; Stewart, C.F.; Houghton, P.J.; Kun, L.E.; Ledet, D.; Gajjar, A. Temozolomide after radiotherapy for newly diagnosed high-grade glioma and unfavorable low-grade glioma in children. J. Neurooncol., 2006, 76(3), 313-319. doi: 10.1007/s11060-005-7409-5 PMID: 16200343
  23. Cohen, K.J.; Pollack, I.F.; Zhou, T.; Buxton, A.; Holmes, E.J.; Burger, P.C.; Brat, D.J.; Rosenblum, M.K.; Hamilton, R.L.; Lavey, R.S.; Heideman, R.L. Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro-oncol., 2011, 13(3), 317-323. doi: 10.1093/neuonc/noq191 PMID: 21339192
  24. Lashford, L.S.; Thiesse, P.; Jouvet, A.; Jaspan, T.; Couanet, D.; Griffiths, P.D.; Doz, F.; Ironside, J.; Robson, K.; Hobson, R.; Dugan, M.; Pearson, A.D.J.; Vassal, G.; Frappaz, D. Temozolomide in malignant gliomas of childhood: A united kingdom children’s cancer study group and french society for pediatric oncology intergroup study. J. Clin. Oncol., 2002, 20(24), 4684-4691. doi: 10.1200/JCO.2002.08.141 PMID: 12488414
  25. Ruggiero, A.; Cefalo, G.; Garré, M.L.; Massimino, M.; Colosimo, C.; Attinà, G.; Lazzareschi, I.; Maurizi, P.; Ridola, V.; Mazzarella, G.; Caldarelli, M.; Rocco, C.D.; Madon, E.; Abate, M.E.; Clerico, A.; Sandri, A.; Riccardi, R. Phase II trial of temozolomide in children with recurrent high-grade glioma. J. Neurooncol., 2006, 77(1), 89-94. doi: 10.1007/s11060-005-9011-2 PMID: 16292488
  26. Korshunov, A.; Ryzhova, M.; Hovestadt, V.; Bender, S.; Sturm, D.; Capper, D.; Meyer, J.; Schrimpf, D.; Kool, M.; Northcott, P.A.; Zheludkova, O.; Milde, T.; Witt, O.; Kulozik, A.E.; Reifenberger, G.; Jabado, N.; Perry, A.; Lichter, P.; von Deimling, A.; Pfister, S.M.; Jones, D.T.W. Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol., 2015, 129(5), 669-678. doi: 10.1007/s00401-015-1405-4 PMID: 25752754
  27. Chassot, A.; Canale, S.; Varlet, P.; Puget, S.; Roujeau, T.; Negretti, L.; Dhermain, F.; Rialland, X.; Raquin, M.A.; Grill, J.; Dufour, C. Radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. J. Neurooncol., 2012, 106(2), 399-407. doi: 10.1007/s11060-011-0681-7 PMID: 21858607
  28. Cohen, K.J.; Heideman, R.L.; Zhou, T.; Holmes, E.J.; Lavey, R.S.; Bouffet, E.; Pollack, I.F. Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro-oncol., 2011, 13(4), 410-416. doi: 10.1093/neuonc/noq205 PMID: 21345842
  29. Hargrave, D.; Bartels, U.; Bouffet, E. Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol., 2006, 7(3), 241-248. doi: 10.1016/S1470-2045(06)70615-5 PMID: 16510333
  30. Rizzo, D.; Scalzone, M.; Ruggiero, A.; Maurizi, P.; Attinà, G.; Mastrangelo, S.; Lazzareschi, I.; Ridola, V.; Colosimo, C.; Caldarelli, M.; Balducci, M.; Riccardi, R. Temozolomide in the treatment of newly diagnosed diffuse brainstem glioma in children: a broken promise? J. Chemother., 2015, 27(2), 106-110. doi: 10.1179/1973947814Y.0000000228 PMID: 25466729
  31. Grasso, C.S.; Tang, Y.; Truffaux, N.; Berlow, N.E.; Liu, L.; Debily, M.A.; Quist, M.J.; Davis, L.E.; Huang, E.C.; Woo, P.J.; Ponnuswami, A.; Chen, S.; Johung, T.B.; Sun, W.; Kogiso, M.; Du, Y.; Qi, L.; Huang, Y.; Hütt-Cabezas, M.; Warren, K.E.; Le Dret, L.; Meltzer, P.S.; Mao, H.; Quezado, M.; van Vuurden, D.G.; Abraham, J.; Fouladi, M.; Svalina, M.N.; Wang, N.; Hawkins, C.; Nazarian, J.; Alonso, M.M.; Raabe, E.H.; Hulleman, E.; Spellman, P.T.; Li, X.N.; Keller, C.; Pal, R.; Grill, J.; Monje, M. Functionally defined therapeutic targets in diffuse intrinsic pontine glioma. Nat. Med., 2015, 21(6), 555-559. doi: 10.1038/nm.3855 PMID: 25939062
  32. Hashizume, R.; Andor, N.; Ihara, Y.; Lerner, R.; Gan, H.; Chen, X.; Fang, D.; Huang, X.; Tom, M.W.; Ngo, V.; Solomon, D.; Mueller, S.; Paris, P.L.; Zhang, Z.; Petritsch, C.; Gupta, N.; Waldman, T.A.; James, C.D. Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nat. Med., 2014, 20(12), 1394-1396. doi: 10.1038/nm.3716 PMID: 25401693
  33. Keir, M.E.; Liang, S.C.; Guleria, I.; Latchman, Y.E.; Qipo, A.; Albacker, L.A.; Koulmanda, M.; Freeman, G.J.; Sayegh, M.H.; Sharpe, A.H. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J. Exp. Med., 2006, 203(4), 883-895. doi: 10.1084/jem.20051776 PMID: 16606670
  34. Ohigashi, Y.; Sho, M.; Yamada, Y.; Tsurui, Y.; Hamada, K.; Ikeda, N.; Mizuno, T.; Yoriki, R.; Kashizuka, H.; Yane, K.; Tsushima, F.; Otsuki, N.; Yagita, H.; Azuma, M.; Nakajima, Y. Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin. Cancer Res., 2005, 11(8), 2947-2953. doi: 10.1158/1078-0432.CCR-04-1469 PMID: 15837746
  35. Patel, S.P.; Kurzrock, R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol. Cancer Ther., 2015, 14(4), 847-856. doi: 10.1158/1535-7163.MCT-14-0983 PMID: 25695955
  36. Lussier, D.M.; O’Neill, L.; Nieves, L.M.; McAfee, M.S.; Holechek, S.A.; Collins, A.W.; Dickman, P.; Jacobsen, J.; Hingorani, P.; Blattman, J.N. Enhanced T-cell immunity to osteosarcoma through antibody blockade of PD-1/PD-L1 interactions. J. Immunother., 2015, 38(3), 96-106. doi: 10.1097/CJI.0000000000000065 PMID: 25751499
  37. Pham, C.D.; Flores, C.; Yang, C.; Pinheiro, E.M.; Yearley, J.H.; Sayour, E.J.; Pei, Y.; Moore, C.; McLendon, R.E.; Huang, J.; Sampson, J.H.; Wechsler-Reya, R.; Mitchell, D.A. Differential immune microenvironments and response to immune checkpoint blockade among molecular subtypes of murine medulloblastoma. Clin. Cancer Res., 2016, 22(3), 582-595. doi: 10.1158/1078-0432.CCR-15-0713 PMID: 26405194
  38. Aoki, T.; Hino, M.; Koh, K.; Kyushiki, M.; Kishimoto, H.; Arakawa, Y.; Hanada, R.; Kawashima, H.; Kurihara, J.; Shimojo, N.; Motohashi, S. Low frequency of programmed death ligand 1 expression in pediatric cancers. Pediatr. Blood Cancer, 2016, 63(8), 1461-1464. doi: 10.1002/pbc.26018 PMID: 27135656
  39. Chowdhury, F.; Dunn, S.; Mitchell, S.; Mellows, T.; Ashton-Key, M.; Gray, J.C. PD-L1 and CD8 + PD1 + lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy. OncoImmunology, 2015, 4(10), e1029701. doi: 10.1080/2162402X.2015.1029701
  40. Kim, C.; Kim, E.K.; Jung, H.; Chon, H.J.; Han, J.W.; Shin, K.H.; Hu, H.; Kim, K.S.; Choi, Y.D.; Kim, S.; Lee, Y.H.; Suh, J.S.; Ahn, J.B.; Chung, H.C.; Noh, S.H.; Rha, S.Y.; Kim, S.H.; Kim, H.S. Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. BMC Cancer, 2016, 16(1), 434. doi: 10.1186/s12885-016-2451-6 PMID: 27393385
  41. Majzner, R.G.; Simon, J.S.; Grosso, J.F.; Martinez, D.; Pawel, B.; Santi-Vincini, M.; Merchant, M.S.; Sorensen, P.; Mackall, C.L.; Maris, J.M. Abstract 249: Assessment of PD-L1 expression and tumor-associated lymphocytes in pediatric cancer tissues. Cancer Res., 2015, 75(15_Supplement)(Suppl.), 249. doi: 10.1158/1538-7445.AM2015-249
  42. Routh, J.C.; Ashley, R.A.; Sebo, T.J.; Lohse, C.M.; Husmann, D.A.; Kramer, S.A.; Kwon, E.D. B7-H1 expression in Wilms tumor: correlation with tumor biology and disease recurrence. J. Urol., 2008, 179(5), 1954-1960. doi: 10.1016/j.juro.2008.01.056 PMID: 18355839
  43. Bhaijee, F.; Anders, R.A. PD-L1 Expression as a Predictive Biomarker. JAMA Oncol., 2016, 2(1), 54-55. doi: 10.1001/jamaoncol.2015.3782 PMID: 26561922
  44. Boes, M.; Meyer-Wentrup, F. TLR3 triggering regulates PD-L1 (CD274) expression in human neuroblastoma cells. Cancer Lett., 2015, 361(1), 49-56. doi: 10.1016/j.canlet.2015.02.027 PMID: 25697485
  45. Usui, Y.; Okunuki, Y.; Hattori, T.; Takeuchi, M.; Kezuka, T.; Goto, H.; Usui, M. Expression of costimulatory molecules on human retinoblastoma cells Y-79: functional expression of CD40 and B7H1. Invest. Ophthalmol. Vis. Sci., 2006, 47(10), 4607-4613. doi: 10.1167/iovs.06-0181 PMID: 17003458
  46. Mao, Y.; Eissler, N.; Blanc, K.L.; Johnsen, J.I.; Kogner, P.; Kiessling, R. Targeting suppressive myeloid cells potentiates checkpoint inhibitors to control spontaneous neuroblastoma. Clin. Cancer Res., 2016, 22(15), 3849-3859. doi: 10.1158/1078-0432.CCR-15-1912 PMID: 26957560
  47. Brahmer, J.; Reckamp, K.L.; Baas, P.; Crinò, L.; Eberhardt, W.E.E.; Poddubskaya, E.; Antonia, S.; Pluzanski, A.; Vokes, E.E.; Holgado, E.; Waterhouse, D.; Ready, N.; Gainor, J.; Arén Frontera, O.; Havel, L.; Steins, M.; Garassino, M.C.; Aerts, J.G.; Domine, M.; Paz-Ares, L.; Reck, M.; Baudelet, C.; Harbison, C.T.; Lestini, B.; Spigel, D.R. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N. Engl. J. Med., 2015, 373(2), 123-135. doi: 10.1056/NEJMoa1504627 PMID: 26028407
  48. Motzer, R.J.; Escudier, B.; McDermott, D.F.; George, S.; Hammers, H.J.; Srinivas, S.; Tykodi, S.S.; Sosman, J.A.; Procopio, G.; Plimack, E.R.; Castellano, D.; Choueiri, T.K.; Gurney, H.; Donskov, F.; Bono, P.; Wagstaff, J.; Gauler, T.C.; Ueda, T.; Tomita, Y.; Schutz, F.A.; Kollmannsberger, C.; Larkin, J.; Ravaud, A.; Simon, J.S.; Xu, L.A.; Waxman, I.M.; Sharma, P. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med., 2015, 373(19), 1803-1813. doi: 10.1056/NEJMoa1510665 PMID: 26406148
  49. Robert, C.; Schachter, J.; Long, G.V.; Arance, A.; Grob, J.J.; Mortier, L.; Daud, A.; Carlino, M.S.; McNeil, C.; Lotem, M.; Larkin, J.; Lorigan, P.; Neyns, B.; Blank, C.U.; Hamid, O.; Mateus, C.; Shapira-Frommer, R.; Kosh, M.; Zhou, H.; Ibrahim, N.; Ebbinghaus, S.; Ribas, A. Pembrolizumab versus ipilimumab in advanced melanoma. N. Engl. J. Med., 2015, 372(26), 2521-2532. doi: 10.1056/NEJMoa1503093 PMID: 25891173
  50. Rosenberg, J.E.; Hoffman-Censits, J.; Powles, T.; van der Heijden, M.S.; Balar, A.V.; Necchi, A.; Dawson, N.; O’Donnell, P.H.; Balmanoukian, A.; Loriot, Y.; Srinivas, S.; Retz, M.M.; Grivas, P.; Joseph, R.W.; Galsky, M.D.; Fleming, M.T.; Petrylak, D.P.; Perez-Gracia, J.L.; Burris, H.A.; Castellano, D.; Canil, C.; Bellmunt, J.; Bajorin, D.; Nickles, D.; Bourgon, R.; Frampton, G.M.; Cui, N.; Mariathasan, S.; Abidoye, O.; Fine, G.D.; Dreicer, R. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet, 2016, 387(10031), 1909-1920. doi: 10.1016/S0140-6736(16)00561-4 PMID: 26952546
  51. Valsecchi, M.E. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med., 2015, 373(13), 1270-1271. doi: 10.1056/NEJMc1509660 PMID: 26398077
  52. Carbognin, L.; Pilotto, S.; Milella, M.; Vaccaro, V.; Brunelli, M.; Caliò, A.; Cuppone, F.; Sperduti, I.; Giannarelli, D.; Chilosi, M.; Bronte, V.; Scarpa, A.; Bria, E.; Tortora, G. Differential activity of nivolumab, pembrolizumab and MPDL3280A according to the tumor expression of programmed death-ligand-1 (PD-L1): Sensitivity analysis of trials in melanoma, lung and genitourinary cancers. PLoS One, 2015, 10(6), e0130142. doi: 10.1371/journal.pone.0130142 PMID: 26086854
  53. Bouffet, E.; Larouche, V.; Campbell, B.B.; Merico, D.; de Borja, R.; Aronson, M.; Durno, C.; Krueger, J.; Cabric, V.; Ramaswamy, V.; Zhukova, N.; Mason, G.; Farah, R.; Afzal, S.; Yalon, M.; Rechavi, G.; Magimairajan, V.; Walsh, M.F.; Constantini, S.; Dvir, R.; Elhasid, R.; Reddy, A.; Osborn, M.; Sullivan, M.; Hansford, J.; Dodgshun, A.; Klauber-Demore, N.; Peterson, L.; Patel, S.; Lindhorst, S.; Atkinson, J.; Cohen, Z.; Laframboise, R.; Dirks, P.; Taylor, M.; Malkin, D.; Albrecht, S.; Dudley, R.W.R.; Jabado, N.; Hawkins, C.E.; Shlien, A.; Tabori, U. Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J. Clin. Oncol., 2016, 34(19), 2206-2211. doi: 10.1200/JCO.2016.66.6552 PMID: 27001570
  54. Alegre, M.L.; Noel, P.J.; Eisfelder, B.J.; Chuang, E.; Clark, M.R.; Reiner, S.L.; Thompson, C.B. Regulation of surface and intracellular expression of CTLA4 on mouse T cells. J. Immunol., 1996, 157(11), 4762-4770. doi: 10.4049/jimmunol.157.11.4762 PMID: 8943377
  55. Linsley, P.S.; Bradshaw, J.; Greene, J.; Peach, R.; Bennett, K.L.; Mittler, R.S. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity, 1996, 4(6), 535-543. doi: 10.1016/S1074-7613(00)80480-X PMID: 8673700
  56. Noel, P.J.; Boise, L.H.; Green, J.M.; Thompson, C.B. CD28 costimulation prevents cell death during primary T cell activation. J. Immunol., 1996, 157(2), 636-642. doi: 10.4049/jimmunol.157.2.636 PMID: 8752911
  57. Wing, K.; Onishi, Y.; Prieto-Martin, P.; Yamaguchi, T.; Miyara, M.; Fehervari, Z.; Nomura, T.; Sakaguchi, S. CTLA-4 control over Foxp3+ regulatory T cell function. Science, 2008, 322(5899), 271-275. doi: 10.1126/science.1160062 PMID: 18845758
  58. Selby, M.J.; Engelhardt, J.J.; Quigley, M.; Henning, K.A.; Chen, T.; Srinivasan, M.; Korman, A.J. Anti-CTLA-4 antibodies of IgG2a isotype enhance antitumor activity through reduction of intratumoral regulatory T cells. Cancer Immunol. Res., 2013, 1(1), 32-42. doi: 10.1158/2326-6066.CIR-13-0013 PMID: 24777248
  59. Peggs, K.S.; Quezada, S.A.; Chambers, C.A.; Korman, A.J.; Allison, J.P. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies. J. Exp. Med., 2009, 206(8), 1717-1725. doi: 10.1084/jem.20082492 PMID: 19581407
  60. Sun, T.; Zhou, Y.; Yang, M.; Hu, Z.; Tan, W.; Han, X.; Shi, Y.; Yao, J.; Guo, Y.; Yu, D.; Tian, T.; Zhou, X.; Shen, H.; Lin, D. Functional genetic variations in cytotoxic T-lymphocyte antigen 4 and susceptibility to multiple types of cancer. Cancer Res., 2008, 68(17), 7025-7034. doi: 10.1158/0008-5472.CAN-08-0806 PMID: 18757416
  61. Yu, F.; Miao, J. Significant association between cytotoxic T lymphocyte antigen 4 +49G>A polymorphism and risk of malignant bone tumors. Tumour Biol., 2013, 34(6), 3371-3375.
  62. Hurwitz, A.A.; Yu, T.F.Y.; Leach, D.R.; Allison, J.P. CTLA-4 blockade synergizes with tumor-derived granulocyte- macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma. Proc. Natl. Acad. Sci. USA, 1998, 95(17), 10067-10071. doi: 10.1073/pnas.95.17.10067 PMID: 9707601
  63. Kwon, E.D.; Hurwitz, A.A.; Foster, B.A.; Madias, C.; Feldhaus, A.L.; Greenberg, N.M.; Burg, M.B.; Allison, J.P. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA, 1997, 94(15), 8099-8103. doi: 10.1073/pnas.94.15.8099 PMID: 9223321
  64. Leach, D.R.; Krummel, M.F.; Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science, 1996, 271(5256), 1734-1736. doi: 10.1126/science.271.5256.1734 PMID: 8596936
  65. Contardi, E.; Palmisano, G.L.; Tazzari, P.L.; Martelli, A.M.; Falà, F.; Fabbi, M.; Kato, T.; Lucarelli, E.; Donati, D.; Polito, L.; Bolognesi, A.; Ricci, F.; Salvi, S.; Gargaglione, V.; Mantero, S.; Alberghini, M.; Ferrara, G.B.; Pistillo, M.P. CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int. J. Cancer, 2005, 117(4), 538-550. doi: 10.1002/ijc.21155 PMID: 15912538
  66. Merchant, M.S.; Wright, M.; Baird, K.; Wexler, L.H.; Rodriguez-Galindo, C.; Bernstein, D.; Delbrook, C.; Lodish, M.; Bishop, R.; Wolchok, J.D.; Streicher, H.; Mackall, C.L.; Phase, I. Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors. Clin. Cancer Res., 2016, 22(6), 1364-1370. doi: 10.1158/1078-0432.CCR-15-0491 PMID: 26534966
  67. Eggermont, A.M.M.; Chiarion-Sileni, V.; Grob, J.J.; Dummer, R.; Wolchok, J.D.; Schmidt, H.; Hamid, O.; Robert, C.; Ascierto, P.A.; Richards, J.M.; Lebbé, C.; Ferraresi, V.; Smylie, M.; Weber, J.S.; Maio, M.; Konto, C.; Hoos, A.; de Pril, V.; Gurunath, R.K.; de Schaetzen, G.; Suciu, S.; Testori, A. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol., 2015, 16(5), 522-530. doi: 10.1016/S1470-2045(15)70122-1 PMID: 25840693
  68. Ribas, A.; Kefford, R.; Marshall, M.A.; Punt, C.J.A.; Haanen, J.B.; Marmol, M.; Garbe, C.; Gogas, H.; Schachter, J.; Linette, G.; Lorigan, P.; Kendra, K.L.; Maio, M.; Trefzer, U.; Smylie, M.; McArthur, G.A.; Dreno, B.; Nathan, P.D.; Mackiewicz, J.; Kirkwood, J.M.; Gomez-Navarro, J.; Huang, B.; Pavlov, D.; Hauschild, A. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J. Clin. Oncol., 2013, 31(5), 616-622. doi: 10.1200/JCO.2012.44.6112 PMID: 23295794
  69. Wright, G.J.; Jones, M.; Puklavec, M.J.; Brown, M.H.; Barclay, A.N. The unusual distribution of the neuronal/lymphoid cell surface CD200 (OX2) glycoprotein is conserved in humans. Immunology, 2001, 102(2), 173-179. doi: 10.1046/j.1365-2567.2001.01163.x PMID: 11260322
  70. Hoek, R.M.; Ruuls, S.R.; Murphy, C.A.; Wright, G.J.; Goddard, R.; Zurawski, S.M.; Blom, B.; Homola, M.E.; Streit, W.J.; Brown, M.H.; Barclay, A.N.; Sedgwick, J.D. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science, 2000, 290(5497), 1768-1771. doi: 10.1126/science.290.5497.1768 PMID: 11099416
  71. Jenmalm, M.C.; Cherwinski, H.; Bowman, E.P.; Phillips, J.H.; Sedgwick, J.D. Regulation of myeloid cell function through the CD200 receptor. J. Immunol., 2006, 176(1), 191-199. doi: 10.4049/jimmunol.176.1.191 PMID: 16365410
  72. Gorczynski, R.M.; Lee, L.; Boudakov, I. Augmented Induction of CD4+CD25+ Treg using monoclonal antibodies to CD200R. Transplantation, 2005, 79(9), 1180-1183. doi: 10.1097/01.TP.0000152118.51622.F9 PMID: 15880066
  73. McWhirter, J.R.; Kretz-Rommel, A.; Saven, A.; Maruyama, T.; Potter, K.N.; Mockridge, C.I.; Ravey, E.P.; Qin, F.; Bowdish, K.S. Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation. Proc. Natl. Acad. Sci. USA, 2006, 103(4), 1041-1046. doi: 10.1073/pnas.0510081103 PMID: 16418292
  74. Kretz-Rommel, A.; Qin, F.; Dakappagari, N.; Ravey, E.P.; McWhirter, J.; Oltean, D.; Frederickson, S.; Maruyama, T.; Wild, M.A.; Nolan, M.J.; Wu, D.; Springhorn, J.; Bowdish, K.S. CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy. J. Immunol., 2007, 178(9), 5595-5605. doi: 10.4049/jimmunol.178.9.5595 PMID: 17442942
  75. Coles, S.J.; Hills, R.K.; Wang, E.C.Y.; Burnett, A.K.; Man, S.; Darley, R.L.; Tonks, A. Increased CD200 expression in acute myeloid leukemia is linked with an increased frequency of FoxP3+ regulatory T cells. Leukemia, 2012, 26(9), 2146-2148. doi: 10.1038/leu.2012.75 PMID: 22430636
  76. Damiani, D.; Tiribelli, M.; Raspadori, D.; Sirianni, S.; Meneghel, A.; Cavalllin, M.; Michelutti, A.; Toffoletti, E.; Geromin, A.; Simeone, E.; Bocchia, M.; Fanin, R. Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors. Oncotarget, 2015, 6(30), 30212-30221. doi: 10.18632/oncotarget.4901 PMID: 26338961
  77. Moertel, C.L.; Xia, J.; LaRue, R.; Waldron, N.N.; Andersen, B.M.; Prins, R.M.; Okada, H.; Donson, A.M.; Foreman, N.K.; Hunt, M.A.; Pennell, C.A.; Olin, M.R. CD200 in CNS tumor-induced immunosuppression: the role for CD200 pathway blockade in targeted immunotherapy. J. Immunother. Cancer, 2014, 2(1), 46. doi: 10.1186/s40425-014-0046-9 PMID: 25598973
  78. Siva, A.; Xin, H.; Qin, F.; Oltean, D.; Bowdish, K.S.; Kretz-Rommel, A. Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200. Cancer Immunol. Immunother., 2008, 57(7), 987-996. doi: 10.1007/s00262-007-0429-6 PMID: 18060403
  79. Alexander, W. American society of hematology, 52nd annual meeting and exposition. PT, 2011, 36(2), 100-103.
  80. Dai, X.; Zhu, B.T. Indoleamine 2,3-dioxygenase tissue distribution and cellular localization in mice: implications for its biological functions. J. Histochem. Cytochem., 2010, 58(1), 17-28. doi: 10.1369/jhc.2009.953604 PMID: 19741271
  81. Guillemin, G.J.; Smythe, G.; Takikawa, O.; Brew, B.J. Expression of indoleamine 2,3-dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons. Glia, 2005, 49(1), 15-23. doi: 10.1002/glia.20090 PMID: 15390107
  82. Takikawa, O. Biochemical and medical aspects of the indoleamine 2,3-dioxygenase-initiated l-tryptophan metabolism. Biochem. Biophys. Res. Commun., 2005, 338(1), 12-19. doi: 10.1016/j.bbrc.2005.09.032 PMID: 16176799
  83. Frumento, G.; Rotondo, R.; Tonetti, M.; Damonte, G.; Benatti, U.; Ferrara, G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med., 2002, 196(4), 459-468. doi: 10.1084/jem.20020121 PMID: 12186838
  84. Werner-Felmayer, G.; Werner, E.R.; Fuchs, D.; Hausen, A.; Reibnegger, G.; Wachter, H. Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim. Biophys. Acta Mol. Cell Res., 1989, 1012(2), 140-147. doi: 10.1016/0167-4889(89)90087-6 PMID: 2500976
  85. Wolf, A.; Wolf, D.; Rumpold, H.; Moschen, A.R.; Kaser, A.; Obrist, P.; Fuchs, D.; Brandacher, G.; Winkler, C.; Geboes, K.; Rutgeerts, P.; Tilg, H. Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease. Clin. Immunol., 2004, 113(1), 47-55. doi: 10.1016/j.clim.2004.05.004 PMID: 15380529
  86. Munn, D.H.; Zhou, M.; Attwood, J.T.; Bondarev, I.; Conway, S.J.; Marshall, B.; Brown, C.; Mellor, A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science, 1998, 281(5380), 1191-1193. doi: 10.1126/science.281.5380.1191 PMID: 9712583
  87. Uyttenhove, C.; Pilotte, L.; Théate, I.; Stroobant, V.; Colau, D.; Parmentier, N.; Boon, T.; Van den Eynde, B.J. Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase. Nat. Med., 2003, 9(10), 1269-1274. doi: 10.1038/nm934 PMID: 14502282
  88. Soliman, H.H.; Minton, S.E.; Han, H.S.; Ismail-Khan, R.; Neuger, A.; Khambati, F.; Noyes, D.; Lush, R.; Chiappori, A.A.; Roberts, J.D.; Link, C.; Vahanian, N.N.; Mautino, M.; Streicher, H.; Sullivan, D.M.; Antonia, S.J. A phase I study of indoximod in patients with advanced malignancies. Oncotarget, 2016, 7(16), 22928-22938. doi: 10.18632/oncotarget.8216 PMID: 27008709
  89. Urakawa, H.; Nishida, Y.; Nakashima, H.; Shimoyama, Y.; Nakamura, S.; Ishiguro, N. Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin. Exp. Metastasis, 2009, 26(8), 1005-1012. doi: 10.1007/s10585-009-9290-7 PMID: 19802733
  90. Chapoval, A.I.; Ni, J.; Lau, J.S.; Wilcox, R.A.; Flies, D.B.; Liu, D.; Dong, H.; Sica, G.L.; Zhu, G.; Tamada, K.; Chen, L. B7-H3: A costimulatory molecule for T cell activation and IFN-γ production. Nat. Immunol., 2001, 2(3), 269-274. doi: 10.1038/85339 PMID: 11224528
  91. Sun, J.; Fu, F.; Gu, W.; Yan, R.; Zhang, G.; Shen, Z.; Zhou, Y.; Wang, H.; Shen, B.; Zhang, X. Origination of new immunological functions in the costimulatory molecule B7-H3: the role of exon duplication in evolution of the immune system. PLoS One, 2011, 6(9), e24751. doi: 10.1371/journal.pone.0024751 PMID: 21931843
  92. Ling, V.; Wu, P.W.; Spaulding, V.; Kieleczawa, J.; Luxenberg, D.; Carreno, B.M.; Collins, M. Duplication of primate and rodent B7-H3 immunoglobulin V- and C-like domains: divergent history of functional redundancy and exon loss. Genomics, 2003, 82(3), 365-377. doi: 10.1016/S0888-7543(03)00126-5 PMID: 12906861
  93. Steinberger, P.; Majdic, O.; Derdak, S.V.; Pfistershammer, K.; Kirchberger, S.; Klauser, C.; Zlabinger, G.; Pickl, W.F.; Stöckl, J.; Knapp, W. Molecular characterization of human 4Ig-B7-H3, a member of the B7 family with four Ig-like domains. J. Immunol., 2004, 172(4), 2352-2359. doi: 10.4049/jimmunol.172.4.2352 PMID: 14764704
  94. Sun, M.; Richards, S.; Prasad, D.V.R.; Mai, X.M.; Rudensky, A.; Dong, C. Characterization of mouse and human B7-H3 genes. J. Immunol., 2002, 168(12), 6294-6297. doi: 10.4049/jimmunol.168.12.6294 PMID: 12055244
  95. Zhou, Y.H.; Chen, Y.J.; Ma, Z.Y.; Xu, L.; Wang, Q.; Zhang, G.B.; Xie, F.; Ge, Y.; Wang, X.F.; Zhang, X.G. 4IgB7-H3 is the major isoform expressed on immunocytes as well as malignant cells. Tissue Antigens, 2007, 70(2), 96-104. doi: 10.1111/j.1399-0039.2007.00853.x PMID: 17610414
  96. Zhang, G.; Hou, J.; Shi, J.; Yu, G.; Lu, B.; Zhang, X. Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. Immunology, 2008, 123(4), 538-546. doi: 10.1111/j.1365-2567.2007.02723.x PMID: 18194267
  97. Picarda, E.; Ohaegbulam, K.C.; Zang, X. Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy. Clin. Cancer Res., 2016, 22(14), 3425-3431. doi: 10.1158/1078-0432.CCR-15-2428 PMID: 27208063
  98. Carreno, B.M.; Collins, M. The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses. Annu. Rev. Immunol., 2002, 20(1), 29-53. doi: 10.1146/annurev.immunol.20.091101.091806 PMID: 11861596
  99. Chen, L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat. Rev. Immunol., 2004, 4(5), 336-347. doi: 10.1038/nri1349 PMID: 15122199
  100. Greenwald, R.J.; Freeman, G.J.; Sharpe, A.H. The B7 family revisited. Annu. Rev. Immunol., 2005, 23(1), 515-548. doi: 10.1146/annurev.immunol.23.021704.115611 PMID: 15771580
  101. Hashiguchi, M.; Kobori, H.; Ritprajak, P.; Kamimura, Y.; Kozono, H.; Azuma, M. Triggering receptor expressed on myeloid cell-like transcript 2 (TLT-2) is a counter-receptor for B7-H3 and enhances T cell responses. Proc. Natl. Acad. Sci. USA, 2008, 105(30), 10495-10500. doi: 10.1073/pnas.0802423105 PMID: 18650384
  102. Prasad, D.V.R.; Nguyen, T.; Li, Z.; Yang, Y.; Duong, J.; Wang, Y.; Dong, C. Murine B7-H3 is a negative regulator of T cells. J. Immunol., 2004, 173(4), 2500-2506. doi: 10.4049/jimmunol.173.4.2500 PMID: 15294965
  103. Mahnke, K.; Ring, S.; Johnson, T.S.; Schallenberg, S.; Schönfeld, K.; Storn, V.; Bedke, T.; Enk, A.H. Induction of immunosuppressive functions of dendritic cells in vivo by CD4+CD25+ regulatory T cells: Role of B7-H3 expression and antigen presentation. Eur. J. Immunol., 2007, 37(8), 2117-2126. doi: 10.1002/eji.200636841 PMID: 17615586
  104. Leitner, J.; Klauser, C.; Pickl, W.F.; Stöckl, J.; Majdic, O.; Bardet, A.F.; Kreil, D.P.; Dong, C.; Yamazaki, T.; Zlabinger, G.; Pfistershammer, K.; Steinberger, P. B7-H3 is a potent inhibitor of human T-cell activation: No evidence for B7-H3 and TREML2 interaction. Eur. J. Immunol., 2009, 39(7), 1754-1764. doi: 10.1002/eji.200839028 PMID: 19544488
  105. Hofmeyer, K.A.; Ray, A.; Zang, X. The contrasting role of B7-H3. Proc. Natl. Acad. Sci. USA, 2008, 105(30), 10277-10278. doi: 10.1073/pnas.0805458105 PMID: 18650376
  106. Petroff, M.G.; Kharatyan, E.; Torry, D.S.; Holets, L. The immunomodulatory proteins B7-DC, B7-H2, and B7-H3 are differentially expressed across gestation in the human placenta. Am. J. Pathol., 2005, 167(2), 465-473. doi: 10.1016/S0002-9440(10)62990-2 PMID: 16049332
  107. Wang, J.; Chong, K.K.; Nakamura, Y.; Nguyen, L.; Huang, S.K.; Kuo, C.; Zhang, W.; Yu, H.; Morton, D.L.; Hoon, D.S.B. B7-H3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J. Invest. Dermatol., 2013, 133(8), 2050-2058. doi: 10.1038/jid.2013.114 PMID: 23474948
  108. Hu, Y.; Lv, X.; Wu, Y.; Xu, J.; Wang, L.; Chen, W.; Zhang, W.; Li, J.; Zhang, S.; Qiu, H. Expression of costimulatory molecule B7-H3 and its prognostic implications in human acute leukemia. Hematology, 2015, 20(4), 187-195. doi: 10.1179/1607845414Y.0000000186 PMID: 25130683
  109. Sun, J.; Guo, Y.; Li, X.; Zhang, Y.; Gu, L.; Wu, P.; Bai, G.; Xiao, Y. B7-H3 expression in breast cancer and upregulation of VEGF through gene silence. OncoTargets Ther., 2014, 7, 1979-1986. doi: 10.2147/OTT.S63424 PMID: 25378933
  110. Zang, X.; Thompson, R.H.; Al-Ahmadie, H.A.; Serio, A.M.; Reuter, V.E.; Eastham, J.A.; Scardino, P.T.; Sharma, P.; Allison, J.P. B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome. Proc. Natl. Acad. Sci. USA, 2007, 104(49), 19458-19463. doi: 10.1073/pnas.0709802104 PMID: 18042703
  111. Zang, X.; Sullivan, P.S.; Soslow, R.A.; Waitz, R.; Reuter, V.E.; Wilton, A. Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas. Modern pathology: an official journal of the United States and Canadian Academy of Pathology. Inc., 2010, 23(8), 1104-1112.
  112. Chen, Y.; Zhao, H.; Zhu, D. zhi; He, S.; Kuang, Y.; Li, D.; Zhang, Z.; Song, S.; Zhang, L.; Sun, J. The coexpression and clinical significance of costimulatory molecules B7-H1, B7-H3, and B7-H4 in human pancreatic cancer. OncoTargets Ther., 2014, 7, 1465-1472. doi: 10.2147/OTT.S66809 PMID: 25170273
  113. Ingebrigtsen, V.A.; Boye, K.; Nesland, J.M.; Nesbakken, A.; Flatmark, K.; Fodstad, Ø. B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer, 2014, 14(1), 602. doi: 10.1186/1471-2407-14-602 PMID: 25139714
  114. Lemke, D.; Pfenning, P.N.; Sahm, F.; Klein, A.C.; Kempf, T.; Warnken, U.; Schnölzer, M.; Tudoran, R.; Weller, M.; Platten, M.; Wick, W. Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness. Clin. Cancer Res., 2012, 18(1), 105-117. doi: 10.1158/1078-0432.CCR-11-0880 PMID: 22080438
  115. Wang, L.; Zhang, Q.; Chen, W.; Shan, B.; Ding, Y.; Zhang, G.; Cao, N.; Liu, L.; Zhang, Y. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PLoS One, 2013, 8(8), e70689. doi: 10.1371/journal.pone.0070689 PMID: 23940627
  116. Ingebrigtsen, V.A.; Boye, K.; Tekle, C.; Nesland, J.M.; Flatmark, K.; Fodstad, Ø. B7-H3 expression in colorectal cancer: Nuclear localization strongly predicts poor outcome in colon cancer. Int. J. Cancer, 2012, 131(11), 2528-2536. doi: 10.1002/ijc.27566 PMID: 22473715
  117. Qin, X.; Zhang, H.; Ye, D.; Dai, B.; Zhu, Y.; Shi, G. B7-H3 is a new cancer-specific endothelial marker in clear cell renal cell carcinoma. OncoTargets Ther., 2013, 6, 1667-1673. doi: 10.2147/OTT.S53565 PMID: 24265557
  118. Bachawal, S.V.; Jensen, K.C.; Wilson, K.E.; Tian, L.; Lutz, A.M.; Willmann, J.K. Breast cancer detection by B7-H3-targeted ultrasound molecular imaging. Cancer Res., 2015, 75(12), 2501-2509. doi: 10.1158/0008-5472.CAN-14-3361 PMID: 25899053
  119. Arigami, T.; Narita, N.; Mizuno, R.; Nguyen, L.; Ye, X.; Chung, A.; Giuliano, A.E.; Hoon, D.S.B. B7-h3 ligand expression by primary breast cancer and associated with regional nodal metastasis. Ann. Surg., 2010, 252(6), 1044-1051. doi: 10.1097/SLA.0b013e3181f1939d PMID: 21107115
  120. Kraan, J.; van den Broek, P.; Verhoef, C.; Grunhagen, D.J.; Taal, W.; Gratama, J.W.; Sleijfer, S. Endothelial CD276 (B7-H3) expression is increased in human malignancies and distinguishes between normal and tumour-derived circulating endothelial cells. Br. J. Cancer, 2014, 111(1), 149-156. doi: 10.1038/bjc.2014.286 PMID: 24892449
  121. Liu, C.; Liu, J.; Wang, J.; Liu, Y.; Zhang, F.; Lin, W.; Gao, A.; Sun, M.; Wang, Y.; Sun, Y. B7-H3 expression in ductal and lobular breast cancer and its association with IL-10. Mol. Med. Rep., 2013, 7(1), 134-138. doi: 10.3892/mmr.2012.1158 PMID: 23128494
  122. Loo, D.; Alderson, R.F.; Chen, F.Z.; Huang, L.; Zhang, W.; Gorlatov, S.; Burke, S.; Ciccarone, V.; Li, H.; Yang, Y.; Son, T.; Chen, Y.; Easton, A.N.; Li, J.C.; Rillema, J.R.; Licea, M.; Fieger, C.; Liang, T.W.; Mather, J.P.; Koenig, S.; Stewart, S.J.; Johnson, S.; Bonvini, E.; Moore, P.A. Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. Clin. Cancer Res., 2012, 18(14), 3834-3845. doi: 10.1158/1078-0432.CCR-12-0715 PMID: 22615450
  123. Maeda, N.; Yoshimura, K.; Yamamoto, S.; Kuramasu, A.; Inoue, M.; Suzuki, N.; Watanabe, Y.; Maeda, Y.; Kamei, R.; Tsunedomi, R.; Shindo, Y.; Inui, M.; Tamada, K.; Yoshino, S.; Hazama, S.; Oka, M. Expression of B7-H3, a potential factor of tumor immune evasion in combination with the number of regulatory T cells, affects against recurrence-free survival in breast cancer patients. Ann. Surg. Oncol., 2014, 21(S4)(Suppl. 4), 546-554. doi: 10.1245/s10434-014-3564-2 PMID: 24562936
  124. Chen, J.T.; Chen, C.H.; Ku, K.L.; Hsiao, M.; Chiang, C.P.; Hsu, T.L.; Chen, M.H.; Wong, C.H. Glycoprotein B7-H3 overexpression and aberrant glycosylation in oral cancer and immune response. Proc. Natl. Acad. Sci. USA, 2015, 112(42), 13057-13062. doi: 10.1073/pnas.1516991112 PMID: 26438868
  125. Biglarian, A.; Hajizadeh, E.; Kazemnejad, A.; Zayeri, F. Determining of prognostic factors in gastric cancer patients using artificial neural networks. APJCP, 2010, 11(2), 533-536. PMID: 20843146
  126. Sun, Y.; Wang, Y.; Zhao, J.; Gu, M.; Giscombe, R.; Lefvert, A.K.; Wang, X. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer, 2006, 53(2), 143-151. doi: 10.1016/j.lungcan.2006.05.012 PMID: 16782226
  127. Chen, C.; Shen, Y.; Qu, Q.X.; Chen, X.Q.; Zhang, X.G.; Huang, J.A. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp. Cell Res., 2013, 319(1), 96-102. doi: 10.1016/j.yexcr.2012.09.006 PMID: 22999863
  128. Lupu, C.M.; Eisenbach, C.; Kuefner, M.A.; Schmidt, J.; Lupu, A.D.; Stremmel, W.; Encke, J. An orthotopic colon cancer model for studying the B7-H3 antitumor effect in vivo. J. Gastrointest. Surg., 2006, 10(5), 635-645. doi: 10.1007/BF03239969 PMID: 16713537
  129. Zhang, W.; Wang, J.; Wang, Y.; Dong, F.; Zhu, M.; Wan, W.; Li, H.; Wu, F.; Yan, X.; Ke, X. B7-H3 silencing by RNAi inhibits tumor progression and enhances chemosensitivity in U937 cells. OncoTargets Ther., 2015, 8, 1721-1733. doi: 10.2147/OTT.S85272 PMID: 26203263
  130. Shapiro, S.D. Matrix metalloproteinase degradation of extracellular matrix: biological consequences. Curr. Opin. Cell Biol., 1998, 10(5), 602-608. doi: 10.1016/S0955-0674(98)80035-5 PMID: 9818170
  131. Chen, Y.W.; Tekle, C.; Fodstad, O. The immunoregulatory protein human B7H3 is a tumor-associated antigen that regulates tumor cell migration and invasion. Curr. Cancer Drug Targets, 2008, 8(5), 404-413. doi: 10.2174/156800908785133141 PMID: 18690846
  132. Liu, F.; Zhang, T.; Zou, S.; Jiang, B.; Hua, D. B7-H3 promotes cell migration and invasion through the Jak2/Stat3/MMP9 signaling pathway in colorectal cancer. Mol. Med. Rep., 2015, 12(4), 5455-5460. doi: 10.3892/mmr.2015.4050 PMID: 26151358
  133. Liu, H.; Tekle, C.; Chen, Y.W.; Kristian, A.; Zhao, Y.; Zhou, M.; Liu, Z.; Ding, Y.; Wang, B.; Mælandsmo, G.M.; Nesland, J.M.; Fodstad, O.; Tan, M. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol. Cancer Ther., 2011, 10(6), 960-971. doi: 10.1158/1535-7163.MCT-11-0072 PMID: 21518725
  134. Zhang, T.; Jiang, B.; Zou, S.T.; Liu, F.; Hua, D. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3. World J. Gastroenterol., 2015, 21(6), 1804-1813. doi: 10.3748/wjg.v21.i6.1804 PMID: 25684945
  135. Kang, F.; Wang, L.; Jia, H.; Li, D.; Li, H.; Zhang, Y.; Sun, D. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int., 2015, 15(1), 45. doi: 10.1186/s12935-015-0195-z PMID: 25908926
  136. Tekle, C.; Nygren, M.K.; Chen, Y.W.; Dybsjord, I.; Nesland, J.M.; Maelandsmo, G.M.; Fodstad, Ø. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int. J. Cancer, 2012, 130(10), 2282-2290. doi: 10.1002/ijc.26238 PMID: 21671471
  137. Xu, L.; Ding, X.; Tan, H.; Qian, J. Correlation between B7-H3 expression and matrix metalloproteinases 2 expression in pancreatic cancer. Cancer Cell Int., 2013, 13(1), 81. doi: 10.1186/1475-2867-13-81 PMID: 23947693
  138. Nunes-Xavier, C.E.; Karlsen, K.F.; Tekle, C.; Pedersen, C.; Øyjord, T.; Hongisto, V.; Nesland, J.M.; Tan, M.; Sahlberg, K.K.; Fodstad, Ø. Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors. Oncotarget, 2016, 7(6), 6891-6901. doi: 10.18632/oncotarget.6902 PMID: 26771843
  139. Lim, S.; Liu, H.; da Silva, L.M.; Arora, R.; Liu, Z.; Phillips, J.B.; Schmitt, D.C.; Vu, T.; McClellan, S.; Lin, Y.; Lin, W.; Piazza, G.A.; Fodstad, O.; Tan, M. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1α. Cancer Res., 2016, 76(8), 2231-2242. doi: 10.1158/0008-5472.CAN-15-1538 PMID: 27197253
  140. Luther, N.; Zhou, Z.; Zanzonico, P.; Cheung, N.K.; Humm, J.; Edgar, M.A. The potential of theragnostic (1)(2)(4)I-8H9 convection-enhanced delivery in diffuse intrinsic pontine glioma. Neuro-oncol., 2014, 16(6), 800-806. doi: 10.1093/neuonc/not298 PMID: 24526309
  141. Modak, S.; Guo, H.F.; Humm, J.L.; Smith-Jones, P.M.; Larson, S.M.; Cheung, N.K.V. Radioimmunotargeting of human rhabdomyosarcoma using monoclonal antibody 8H9. Cancer Biother. Radiopharm., 2005, 20(5), 534-546. doi: 10.1089/cbr.2005.20.534 PMID: 16248769
  142. Ahmed, M.; Cheng, M.; Zhao, Q.; Goldgur, Y.; Cheal, S.M.; Guo, H.F.; Larson, S.M.; Cheung, N.K.V. Humanized Affinity-matured monoclonal antibody 8H9 has potent antitumor activity and binds to FG loop of tumor antigen B7-H3. J. Biol. Chem., 2015, 290(50), 30018-30029. doi: 10.1074/jbc.M115.679852 PMID: 26487718
  143. Kramer, K.; Kushner, B.H.; Modak, S.; Pandit-Taskar, N.; Smith-Jones, P.; Zanzonico, P.; Humm, J.L.; Xu, H.; Wolden, S.L.; Souweidane, M.M.; Larson, S.M.; Cheung, N.K.V. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J. Neurooncol., 2010, 97(3), 409-418. doi: 10.1007/s11060-009-0038-7 PMID: 19890606
  144. Shi, Z.; Hu, Y.; Chen, H.; Fu, F.; Zhang, X. Identification and characterization of monoclonal antibody Y4F11 against human B7-H3. XiBao Yu FenZi Mian Yi X ue ZaZ hi, 2016, 32(10), 1402-1406.
  145. Xu, H.; Cheung, I.Y.; Guo, H.F.; Cheung, N.K.V. MicroRNA miR-29 modulates expression of immunoinhibitory molecule B7-H3: potential implications for immune based therapy of human solid tumors. Cancer Res., 2009, 69(15), 6275-6281. doi: 10.1158/0008-5472.CAN-08-4517 PMID: 19584290
  146. Li, B.; VanRoey, M.; Triebel, F.; Jooss, K. Lymphocyte activation gene-3 fusion protein increases the potency of a granulocyte macrophage colony-stimulating factor-secreting tumor cell immunotherapy. Clin. Cancer Res., 2008, 14(11), 3545-3554. doi: 10.1158/1078-0432.CCR-07-5200 PMID: 18519788
  147. Yan, J.; Kong, L.Y.; Hu, J.; Gabrusiewicz, K.; Dibra, D.; Xia, X.; Heimberger, A.B.; Li, S. FGL2 as a multimodality regulator of tumor-mediated immune suppression and therapeutic target in gliomas. J. Natl. Cancer Inst., 2015, 107(8), djv137. doi: 10.1093/jnci/djv137 PMID: 25971300
  148. Sakuishi, K.; Apetoh, L.; Sullivan, J.M.; Blazar, B.R.; Kuchroo, V.K.; Anderson, A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med., 2010, 207(10), 2187-2194. doi: 10.1084/jem.20100643 PMID: 20819927
  149. Wang, L.; Rubinstein, R.; Lines, J.L.; Wasiuk, A.; Ahonen, C.; Guo, Y.; Lu, L.F.; Gondek, D.; Wang, Y.; Fava, R.A.; Fiser, A.; Almo, S.; Noelle, R.J. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med., 2011, 208(3), 577-592. doi: 10.1084/jem.20100619 PMID: 21383057
  150. Fan, X.; Quezada, S.A.; Sepulveda, M.A.; Sharma, P.; Allison, J.P. Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy. J. Exp. Med., 2014, 211(4), 715-725. doi: 10.1084/jem.20130590 PMID: 24687957
  151. Curti, B.D.; Kovacsovics-Bankowski, M.; Morris, N.; Walker, E.; Chisholm, L.; Floyd, K.; Walker, J.; Gonzalez, I.; Meeuwsen, T.; Fox, B.A.; Moudgil, T.; Miller, W.; Haley, D.; Coffey, T.; Fisher, B.; Delanty-Miller, L.; Rymarchyk, N.; Kelly, T.; Crocenzi, T.; Bernstein, E.; Sanborn, R.; Urba, W.J.; Weinberg, A.D. OX40 is a potent immune-stimulating target in late-stage cancer patients. Cancer Res., 2013, 73(24), 7189-7198. doi: 10.1158/0008-5472.CAN-12-4174 PMID: 24177180
  152. Melero, I.; Shuford, W.W.; Newby, S.A.; Aruffo, A.; Ledbetter, J.A.; Hellström, K.E.; Mittler, R.S.; Chen, L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med., 1997, 3(6), 682-685. doi: 10.1038/nm0697-682 PMID: 9176498
  153. Janjigian, Y.Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Campos Bragagnoli, A.; Liu, T.; Schenker, M.; Yanez, P.; Tehfe, M.; Kowalyszyn, R.; Karamouzis, M.V.; Bruges, R.; Zander, T.; Pazo-Cid, R.; Hitre, E.; Feeney, K.; Cleary, J.M.; Poulart, V.; Cullen, D.; Lei, M.; Xiao, H.; Kondo, K.; Li, M.; Ajani, J.A. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet, 2021, 398(10294), 27-40. doi: 10.1016/S0140-6736(21)00797-2 PMID: 34102137
  154. Migden, M.R.; Rischin, D.; Schmults, C.D.; Guminski, A.; Hauschild, A.; Lewis, K.D.; Chung, C.H.; Hernandez-Aya, L.; Lim, A.M.; Chang, A.L.S.; Rabinowits, G.; Thai, A.A.; Dunn, L.A.; Hughes, B.G.M.; Khushalani, N.I.; Modi, B.; Schadendorf, D.; Gao, B.; Seebach, F.; Li, S.; Li, J.; Mathias, M.; Booth, J.; Mohan, K.; Stankevich, E.; Babiker, H.M.; Brana, I.; Gil-Martin, M.; Homsi, J.; Johnson, M.L.; Moreno, V.; Niu, J.; Owonikoko, T.K.; Papadopoulos, K.P.; Yancopoulos, G.D.; Lowy, I.; Fury, M.G. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N. Engl. J. Med., 2018, 379(4), 341-351. doi: 10.1056/NEJMoa1805131 PMID: 29863979
  155. Cho, B.C.; Abreu, D.R.; Hussein, M.; Cobo, M.; Patel, A.J.; Secen, N.; Lee, K.H.; Massuti, B.; Hiret, S.; Yang, J.C.H.; Barlesi, F.; Lee, D.H.; Ares, L.P.; Hsieh, R.W.; Patil, N.S.; Twomey, P.; Yang, X.; Meng, R.; Johnson, M.L. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol., 2022, 23(6), 781-792. doi: 10.1016/S1470-2045(22)00226-1 PMID: 35576957
  156. Powles, T.; Park, S.H.; Voog, E.; Caserta, C.; Valderrama, B.P.; Gurney, H.; Kalofonos, H. Radulović S.; Demey, W.; Ullén, A.; Loriot, Y.; Sridhar, S.S.; Tsuchiya, N.; Kopyltsov, E.; Sternberg, C.N.; Bellmunt, J.; Aragon-Ching, J.B.; Petrylak, D.P.; Laliberte, R.; Wang, J.; Huang, B.; Davis, C.; Fowst, C.; Costa, N.; Blake-Haskins, J.A.; di Pietro, A.; Grivas, P. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N. Engl. J. Med., 2020, 383(13), 1218-1230. doi: 10.1056/NEJMoa2002788 PMID: 32945632
  157. Rizzo, A.; Ricci, A.D.; Brandi, G. Durvalumab: an investigational anti-PD-L1 antibody for the treatment of biliary tract cancer. Expert Opin. Investig. Drugs, 2021, 30(4), 343-350. doi: 10.1080/13543784.2021.1897102 PMID: 33645367
  158. Wolchok, J.D.; Kluger, H.; Callahan, M.K.; Postow, M.A.; Rizvi, N.A.; Lesokhin, A.M.; Segal, N.H.; Ariyan, C.E.; Gordon, R.A.; Reed, K.; Burke, M.M.; Caldwell, A.; Kronenberg, S.A.; Agunwamba, B.U.; Zhang, X.; Lowy, I.; Inzunza, H.D.; Feely, W.; Horak, C.E.; Hong, Q.; Korman, A.J.; Wigginton, J.M.; Gupta, A.; Sznol, M. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med., 2013, 369(2), 122-133. doi: 10.1056/NEJMoa1302369 PMID: 23724867
  159. Kelley, R.K.; Sangro, B.; Harris, W.; Ikeda, M.; Okusaka, T.; Kang, Y.K.; Qin, S.; Tai, D.W.M.; Lim, H.Y.; Yau, T.; Yong, W.P.; Cheng, A.L.; Gasbarrini, A.; Damian, S.; Bruix, J.; Borad, M.; Bendell, J.; Kim, T.Y.; Standifer, N.; He, P.; Makowsky, M.; Negro, A.; Kudo, M.; Abou-Alfa, G.K. Safety, efficacy, and pharmacodynamics of tremelimumab plus durvalumab for patients with unresectable hepatocellular carcinoma: randomized expansion of a phase I/II study. J. Clin. Oncol., 2021, 39(27), 2991-3001. doi: 10.1200/JCO.20.03555 PMID: 34292792
  160. Sordo-Bahamonde, C.; Lorenzo-Herrero, S.; González-Rodríguez, A.P.; Payer, Á.R.; González-García, E.; López-Soto, A.; Gonzalez, S. LAG-3 blockade with relatlimab (BMS-986016) restores anti-leukemic responses in chronic lymphocytic leukemia. Cancers (Basel), 2021, 13(9), 2112. doi: 10.3390/cancers13092112 PMID: 33925565
  161. Chocarro, L.; Bocanegra, A.; Blanco, E.; Fernández-Rubio, L.; Arasanz, H.; Echaide, M.; Garnica, M.; Ramos, P.; Piñeiro-Hermida, S.; Vera, R.; Escors, D.; Kochan, G. Cutting-Edge: preclinical and clinical development of the first approved Lag-3 inhibitor. Cells, 2022, 11(15), 2351. doi: 10.3390/cells11152351 PMID: 35954196
  162. Kumar, S.; Jaipuri, F.A.; Waldo, J.P.; Potturi, H.; Marcinowicz, A.; Adams, J.; Van Allen, C.; Zhuang, H.; Vahanian, N.; Link, C., Jr; Brincks, E.L.; Mautino, M.R. Discovery of indoximod prodrugs and characterization of clinical candidate NLG802. Eur. J. Med. Chem., 2020, 198, 112373. doi: 10.1016/j.ejmech.2020.112373 PMID: 32422549
  163. Long, G.V.; Dummer, R.; Hamid, O.; Gajewski, T.F.; Caglevic, C.; Dalle, S.; Arance, A.; Carlino, M.S.; Grob, J.J.; Kim, T.M.; Demidov, L.; Robert, C.; Larkin, J.; Anderson, J.R.; Maleski, J.; Jones, M.; Diede, S.J.; Mitchell, T.C. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol., 2019, 20(8), 1083-1097. doi: 10.1016/S1470-2045(19)30274-8 PMID: 31221619
  164. Nayak-Kapoor, A.; Hao, Z.; Sadek, R.; Dobbins, R.; Marshall, L.; Vahanian, N.N.; Jay Ramsey, W.; Kennedy, E.; Mautino, M.R.; Link, C.J.; Lin, R.S.; Royer-Joo, S.; Liang, X.; Salphati, L.; Morrissey, K.M.; Mahrus, S.; McCall, B.; Pirzkall, A.; Munn, D.H.; Janik, J.E.; Khleif, S.N. Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors. J. Immunother. Cancer, 2018, 6(1), 61. doi: 10.1186/s40425-018-0351-9 PMID: 29921320
  165. Ferris, R.L.; Jaffee, E.M.; Ferrone, S. Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J. Clin. Oncol., 2010, 28(28), 4390-4399. doi: 10.1200/JCO.2009.27.6360 PMID: 20697078
  166. Okada, H.; Low, K.L.; Kohanbash, G.; McDonald, H.A.; Hamilton, R.L.; Pollack, I.F. Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. J. Neurooncol., 2008, 88(3), 245-250. doi: 10.1007/s11060-008-9566-9 PMID: 18324354
  167. Yang, M.; Xie, W.; Mostaghel, E.; Nakabayashi, M.; Werner, L.; Sun, T.; Pomerantz, M.; Freedman, M.; Ross, R.; Regan, M.; Sharifi, N.; Figg, W.D.; Balk, S.; Brown, M.; Taplin, M.E.; Oh, W.K.; Lee, G.S.M.; Kantoff, P.W. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J. Clin. Oncol., 2011, 29(18), 2565-2573. doi: 10.1200/JCO.2010.31.2405 PMID: 21606417
  168. Zhu, Z.; Zhong, S.; Shen, Z. Targeting the inflammatory pathways to enhance chemotherapy of cancer. Cancer Biol. Ther., 2011, 12(2), 95-105. doi: 10.4161/cbt.12.2.15952 PMID: 21623164
  169. Curtin, J.; King, G.; Candolfi, M.; Greeno, R.; Kroeger, K.; Lowenstein, P.; Castro, M. Combining cytotoxic and immune-mediated gene therapy to treat brain tumors. Curr. Top. Med. Chem., 2005, 5(12), 1151-1170. doi: 10.2174/156802605774370856 PMID: 16248789
  170. Ohm, J.E.; McGarvey, K.M.; Yu, X.; Cheng, L.; Schuebel, K.E.; Cope, L.; Mohammad, H.P.; Chen, W.; Daniel, V.C.; Yu, W.; Berman, D.M.; Jenuwein, T.; Pruitt, K.; Sharkis, S.J.; Watkins, D.N.; Herman, J.G.; Baylin, S.B. A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat. Genet., 2007, 39(2), 237-242. doi: 10.1038/ng1972 PMID: 17211412
  171. Haberland, M.; Montgomery, R.L.; Olson, E.N. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat. Rev. Genet., 2009, 10(1), 32-42. doi: 10.1038/nrg2485 PMID: 19065135
  172. Shi, Y. Histone lysine demethylases: emerging roles in development, physiology and disease. Nat. Rev. Genet., 2007, 8(11), 829-833. doi: 10.1038/nrg2218 PMID: 17909537
  173. Lucio-Eterovic, A.K.B.; Cortez, M.A.A.; Valera, E.T.; Motta, F.J.N.; Queiroz, R.G.P.; Machado, H.R.; Carlotti, C.G., Jr; Neder, L.; Scrideli, C.A.; Tone, L.G. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer, 2008, 8(1), 243. doi: 10.1186/1471-2407-8-243 PMID: 18713462
  174. Parsons, D.W.; Jones, S.; Zhang, X.; Lin, J.C.H.; Leary, R.J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.M.; Gallia, G.L.; Olivi, A.; McLendon, R.; Rasheed, B.A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D.A.; Tekleab, H.; Diaz, L.A., Jr; Hartigan, J.; Smith, D.R.; Strausberg, R.L.; Marie, S.K.N.; Shinjo, S.M.O.; Yan, H.; Riggins, G.J.; Bigner, D.D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V.E.; Kinzler, K.W. An integrated genomic analysis of human glioblastoma multiforme. Science, 2008, 321(5897), 1807-1812. doi: 10.1126/science.1164382 PMID: 18772396
  175. Leung, C.; Lingbeek, M.; Shakhova, O.; Liu, J.; Tanger, E.; Saremaslani, P.; van Lohuizen, M.; Marino, S. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature, 2004, 428(6980), 337-341. doi: 10.1038/nature02385 PMID: 15029199
  176. Milde, T.; Oehme, I.; Korshunov, A.; Kopp-Schneider, A.; Remke, M.; Northcott, P.; Deubzer, H.E.; Lodrini, M.; Taylor, M.D.; von Deimling, A.; Pfister, S.; Witt, O. HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth. Clin. Cancer Res., 2010, 16(12), 3240-3252. doi: 10.1158/1078-0432.CCR-10-0395 PMID: 20413433
  177. Sturm, D.; Bender, S.; Jones, D.T.W.; Lichter, P.; Grill, J.; Becher, O.; Hawkins, C.; Majewski, J.; Jones, C.; Costello, J.F.; Iavarone, A.; Aldape, K.; Brennan, C.W.; Jabado, N.; Pfister, S.M. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. Nat. Rev. Cancer, 2014, 14(2), 92-107. doi: 10.1038/nrc3655 PMID: 24457416
  178. Wu, G.; Broniscer, A.; McEachron, T.A.; Lu, C.; Paugh, B.S.; Becksfort, J.; Qu, C.; Ding, L.; Huether, R.; Parker, M.; Zhang, J.; Gajjar, A.; Dyer, M.A.; Mullighan, C.G.; Gilbertson, R.J.; Mardis, E.R.; Wilson, R.K.; Downing, J.R.; Ellison, D.W.; Zhang, J.; Baker, S.J. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat. Genet., 2012, 44(3), 251-253. doi: 10.1038/ng.1102 PMID: 22286216
  179. Buczkowicz, P.; Hoeman, C.; Rakopoulos, P.; Pajovic, S.; Letourneau, L.; Dzamba, M.; Morrison, A.; Lewis, P.; Bouffet, E.; Bartels, U.; Zuccaro, J.; Agnihotri, S.; Ryall, S.; Barszczyk, M.; Chornenkyy, Y.; Bourgey, M.; Bourque, G.; Montpetit, A.; Cordero, F.; Castelo-Branco, P.; Mangerel, J.; Tabori, U.; Ho, K.C.; Huang, A.; Taylor, K.R.; Mackay, A.; Bendel, A.E.; Nazarian, J.; Fangusaro, J.R.; Karajannis, M.A.; Zagzag, D.; Foreman, N.K.; Donson, A.; Hegert, J.V.; Smith, A.; Chan, J.; Lafay-Cousin, L.; Dunn, S.; Hukin, J.; Dunham, C.; Scheinemann, K.; Michaud, J.; Zelcer, S.; Ramsay, D.; Cain, J.; Brennan, C.; Souweidane, M.M.; Jones, C.; Allis, C.D.; Brudno, M.; Becher, O.; Hawkins, C. Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat. Genet., 2014, 46(5), 451-456. doi: 10.1038/ng.2936 PMID: 24705254
  180. Fontebasso, A.M.; Papillon-Cavanagh, S.; Schwartzentruber, J.; Nikbakht, H.; Gerges, N.; Fiset, P.O.; Bechet, D.; Faury, D.; De Jay, N.; Ramkissoon, L.A.; Corcoran, A.; Jones, D.T.W.; Sturm, D.; Johann, P.; Tomita, T.; Goldman, S.; Nagib, M.; Bendel, A.; Goumnerova, L.; Bowers, D.C.; Leonard, J.R.; Rubin, J.B.; Alden, T.; Browd, S.; Geyer, J.R.; Leary, S.; Jallo, G.; Cohen, K.; Gupta, N.; Prados, M.D.; Carret, A.S.; Ellezam, B.; Crevier, L.; Klekner, A.; Bognar, L.; Hauser, P.; Garami, M.; Myseros, J.; Dong, Z.; Siegel, P.M.; Malkin, H.; Ligon, A.H.; Albrecht, S.; Pfister, S.M.; Ligon, K.L.; Majewski, J.; Jabado, N.; Kieran, M.W. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat. Genet., 2014, 46(5), 462-466. doi: 10.1038/ng.2950 PMID: 24705250
  181. Taylor, K.R.; Mackay, A.; Truffaux, N.; Butterfield, Y.S.; Morozova, O.; Philippe, C.; Castel, D.; Grasso, C.S.; Vinci, M.; Carvalho, D.; Carcaboso, A.M.; de Torres, C.; Cruz, O.; Mora, J.; Entz-Werle, N.; Ingram, W.J.; Monje, M.; Hargrave, D.; Bullock, A.N.; Puget, S.; Yip, S.; Jones, C.; Grill, J. Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat. Genet., 2014, 46(5), 457-461. doi: 10.1038/ng.2925 PMID: 24705252
  182. Wu, G.; Diaz, A.K.; Paugh, B.S.; Rankin, S.L.; Ju, B.; Li, Y.; Zhu, X.; Qu, C.; Chen, X.; Zhang, J.; Easton, J.; Edmonson, M.; Ma, X.; Lu, C.; Nagahawatte, P.; Hedlund, E.; Rusch, M.; Pounds, S.; Lin, T.; Onar-Thomas, A.; Huether, R.; Kriwacki, R.; Parker, M.; Gupta, P.; Becksfort, J.; Wei, L.; Mulder, H.L.; Boggs, K.; Vadodaria, B.; Yergeau, D.; Russell, J.C.; Ochoa, K.; Fulton, R.S.; Fulton, L.L.; Jones, C.; Boop, F.A.; Broniscer, A.; Wetmore, C.; Gajjar, A.; Ding, L.; Mardis, E.R.; Wilson, R.K.; Taylor, M.R.; Downing, J.R.; Ellison, D.W.; Zhang, J.; Baker, S.J. The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat. Genet., 2014, 46(5), 444-450. doi: 10.1038/ng.2938 PMID: 24705251
  183. Henikoff, S.; Smith, M.M. Histone variants and epigenetics. Cold Spring Harb. Perspect. Biol., 2015, 7(1), a019364. doi: 10.1101/cshperspect.a019364 PMID: 25561719
  184. Panagopoulos, I.; Fioretos, T.; Isaksson, M.; Samuelsson, U.; Billström, R.; Strömbeck, B.; Mitelman, F.; Johansson, B. Fusion of the MORF and CBP genes in acute myeloid leukemia with the t(10;16)(q22;p13). Hum. Mol. Genet., 2001, 10(4), 395-404. doi: 10.1093/hmg/10.4.395 PMID: 11157802
  185. Zhu, C.; Qin, Y-R.; Xie, D.; Chua, D.T.T.; Fung, J.M.; Chen, L.; Fu, L.; Hu, L.; Guan, X-Y. Characterization of tumor suppressive function of P300/CBP-associated factor at frequently deleted region 3p24 in esophageal squamous cell carcinoma. Oncogene, 2009, 28(31), 2821-2828. doi: 10.1038/onc.2009.137 PMID: 19525977
  186. Bracken, A.P.; Pasini, D.; Capra, M.; Prosperini, E.; Colli, E.; Helin, K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J., 2003, 22(20), 5323-5335. doi: 10.1093/emboj/cdg542 PMID: 14532106
  187. Miremadi, A.; Oestergaard, M.Z.; Pharoah, P.D.P.; Caldas, C. Cancer genetics of epigenetic genes. Hum. Mol. Genet., 2007, 16(R1), R28-R49. doi: 10.1093/hmg/ddm021 PMID: 17613546
  188. Jaju, R.J.; Fidler, C.; Haas, O.A.; Strickson, A.J.; Watkins, F.; Clark, K.; Cross, N.C.; Cheng, J.F.; Aplan, P.D.; Kearney, L.; Boultwood, J.; Wainscoat, J.S. A novel gene, NSD1, is fused to NUP98 in the t(5;11)(q35;p15.5) in de novo childhood acute myeloid leukemia. Blood, 2001, 98(4), 1264-1267. doi: 10.1182/blood.V98.4.1264 PMID: 11493482
  189. Du, Y.; Carling, T.; Fang, W.; Piao, Z.; Sheu, J.C.; Huang, S. Hypermethylation in human cancers of the RIZ1 tumor suppressor gene, a member of a histone/protein methyltransferase superfamily. Cancer Res., 2001, 61(22), 8094-8099. PMID: 11719434
  190. Italiano, A.; Attias, R.; Aurias, A.; Pérot, G.; Burel-Vandenbos, F.; Otto, J.; Venissac, N.; Pedeutour, F. Molecular cytogenetic characterization of a metastatic lung sarcomatoid carcinoma: 9p23 neocentromere and 9p23-p24 amplification including JAK2 and JMJD2C. Cancer Genet. Cytogenet., 2006, 167(2), 122-130. doi: 10.1016/j.cancergencyto.2006.01.004 PMID: 16737911
  191. Liu, G.; Bollig-Fischer, A.; Kreike, B.; van de Vijver, M.J.; Abrams, J.; Ethier, S.P.; Yang, Z.Q. Genomic amplification and oncogenic properties of the GASC1 histone demethylase gene in breast cancer. Oncogene, 2009, 28(50), 4491-4500. doi: 10.1038/onc.2009.297 PMID: 19784073
  192. Kahl, P.; Gullotti, L.; Heukamp, L.C.; Wolf, S.; Friedrichs, N.; Vorreuther, R.; Solleder, G.; Bastian, P.J.; Ellinger, J.; Metzger, E.; Schüle, R.; Buettner, R. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res., 2006, 66(23), 11341-11347. doi: 10.1158/0008-5472.CAN-06-1570 PMID: 17145880
  193. Ropero, S.; Fraga, M.F.; Ballestar, E.; Hamelin, R.; Yamamoto, H.; Boix-Chornet, M.; Caballero, R.; Alaminos, M.; Setien, F.; Paz, M.F.; Herranz, M.; Palacios, J.; Arango, D.; Orntoft, T.F.; Aaltonen, L.A.; Schwartz, S., Jr; Esteller, M. A truncating mutation of HDAC2 in human cancers confers resistance to histone deacetylase inhibition. Nat. Genet., 2006, 38(5), 566-569. doi: 10.1038/ng1773 PMID: 16642021
  194. Faria, C.M.C.; Rutka, J.T.; Smith, C.; Kongkham, P. Epigenetic mechanisms regulating neural development and pediatric brain tumor formation. J. Neurosurg. Pediatr., 2011, 8(2), 119-132. doi: 10.3171/2011.5.PEDS1140 PMID: 21806352
  195. Grossniklaus, U.; Paro, R. Transcriptional silencing by polycomb-group proteins. Cold Spring Harb. Perspect. Biol., 2014, 6(11), a019331. doi: 10.1101/cshperspect.a019331 PMID: 25367972
  196. Lewis, P.W.; Müller, M.M.; Koletsky, M.S.; Cordero, F.; Lin, S.; Banaszynski, L.A.; Garcia, B.A.; Muir, T.W.; Becher, O.J.; Allis, C.D. Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma. Science, 2013, 340(6134), 857-861. doi: 10.1126/science.1232245 PMID: 23539183
  197. Viré, E.; Brenner, C.; Deplus, R.; Blanchon, L.; Fraga, M.; Didelot, C.; Morey, L.; Van Eynde, A.; Bernard, D.; Vanderwinden, J.M.; Bollen, M.; Esteller, M.; Di Croce, L.; de Launoit, Y.; Fuks, F. The Polycomb group protein EZH2 directly controls DNA methylation. Nature, 2006, 439(7078), 871-874. doi: 10.1038/nature04431 PMID: 16357870
  198. Zheng, S.; Houseman, E.A.; Morrison, Z.; Wrensch, M.R.; Patoka, J.S.; Ramos, C.; Haas-Kogan, D.A.; McBride, S.; Marsit, C.J.; Christensen, B.C.; Nelson, H.H.; Stokoe, D.; Wiemels, J.L.; Chang, S.M.; Prados, M.D.; Tihan, T.; Vandenberg, S.R.; Kelsey, K.T.; Berger, M.S.; Wiencke, J.K. DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro-oncol., 2011, 13(3), 280-289. doi: 10.1093/neuonc/noq190 PMID: 21339190
  199. Lewis, P.W.; Allis, C.D. Poisoning the "histone code" in pediatric gliomagenesis. Cell Cycle, 2013, 12(20), 3241-3242. doi: 10.4161/cc.26356 PMID: 24036540
  200. Behjati, S.; Tarpey, P.S.; Presneau, N.; Scheipl, S.; Pillay, N.; Van Loo, P.; Wedge, D.C.; Cooke, S.L.; Gundem, G.; Davies, H.; Nik-Zainal, S.; Martin, S.; McLaren, S.; Goody, V.; Robinson, B.; Butler, A.; Teague, J.W.; Halai, D.; Khatri, B.; Myklebost, O.; Baumhoer, D.; Jundt, G.; Hamoudi, R.; Tirabosco, R.; Amary, M.F.; Futreal, P.A.; Stratton, M.R.; Campbell, P.J.; Flanagan, A.M. Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone. Nat. Genet., 2013, 45(12), 1479-1482. doi: 10.1038/ng.2814 PMID: 24162739
  201. Sturm, D.; Witt, H.; Hovestadt, V.; Khuong-Quang, D.A.; Jones, D.T.W.; Konermann, C.; Pfaff, E.; Tönjes, M.; Sill, M.; Bender, S.; Kool, M.; Zapatka, M.; Becker, N.; Zucknick, M.; Hielscher, T.; Liu, X.Y.; Fontebasso, A.M.; Ryzhova, M.; Albrecht, S.; Jacob, K.; Wolter, M.; Ebinger, M.; Schuhmann, M.U.; van Meter, T.; Frühwald, M.C.; Hauch, H.; Pekrun, A.; Radlwimmer, B.; Niehues, T.; von Komorowski, G.; Dürken, M.; Kulozik, A.E.; Madden, J.; Donson, A.; Foreman, N.K.; Drissi, R.; Fouladi, M.; Scheurlen, W.; von Deimling, A.; Monoranu, C.; Roggendorf, W.; Herold-Mende, C.; Unterberg, A.; Kramm, C.M.; Felsberg, J.; Hartmann, C.; Wiestler, B.; Wick, W.; Milde, T.; Witt, O.; Lindroth, A.M.; Schwartzentruber, J.; Faury, D.; Fleming, A.; Zakrzewska, M.; Liberski, P.P.; Zakrzewski, K.; Hauser, P.; Garami, M.; Klekner, A.; Bognar, L.; Morrissy, S.; Cavalli, F.; Taylor, M.D.; van Sluis, P.; Koster, J.; Versteeg, R.; Volckmann, R.; Mikkelsen, T.; Aldape, K.; Reifenberger, G.; Collins, V.P.; Majewski, J.; Korshunov, A.; Lichter, P.; Plass, C.; Jabado, N.; Pfister, S.M. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell, 2012, 22(4), 425-437. doi: 10.1016/j.ccr.2012.08.024 PMID: 23079654
  202. Schwartzentruber, J.; Korshunov, A.; Liu, X.Y.; Jones, D.T.W.; Pfaff, E.; Jacob, K.; Sturm, D.; Fontebasso, A.M.; Quang, D.A.K.; Tönjes, M.; Hovestadt, V.; Albrecht, S.; Kool, M.; Nantel, A.; Konermann, C.; Lindroth, A.; Jäger, N.; Rausch, T.; Ryzhova, M.; Korbel, J.O.; Hielscher, T.; Hauser, P.; Garami, M.; Klekner, A.; Bognar, L.; Ebinger, M.; Schuhmann, M.U.; Scheurlen, W.; Pekrun, A.; Frühwald, M.C.; Roggendorf, W.; Kramm, C.; Dürken, M.; Atkinson, J.; Lepage, P.; Montpetit, A.; Zakrzewska, M.; Zakrzewski, K.; Liberski, P.P.; Dong, Z.; Siegel, P.; Kulozik, A.E.; Zapatka, M.; Guha, A.; Malkin, D.; Felsberg, J.; Reifenberger, G.; von Deimling, A.; Ichimura, K.; Collins, V.P.; Witt, H.; Milde, T.; Witt, O.; Zhang, C.; Castelo-Branco, P.; Lichter, P.; Faury, D.; Tabori, U.; Plass, C.; Majewski, J.; Pfister, S.M.; Jabado, N. Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature, 2012, 482(7384), 226-231. doi: 10.1038/nature10833 PMID: 22286061
  203. Lovejoy, C.A.; Li, W.; Reisenweber, S.; Thongthip, S.; Bruno, J.; de Lange, T.; De, S.; Petrini, J.H.J.; Sung, P.A.; Jasin, M.; Rosenbluh, J.; Zwang, Y.; Weir, B.A.; Hatton, C.; Ivanova, E.; Macconaill, L.; Hanna, M.; Hahn, W.C.; Lue, N.F.; Reddel, R.R.; Jiao, Y.; Kinzler, K.; Vogelstein, B.; Papadopoulos, N.; Meeker, A.K. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet., 2012, 8(7), e1002772. doi: 10.1371/journal.pgen.1002772 PMID: 22829774
  204. Marks, P.A.; Xu, W.S. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell. Biochem., 2009, 107(4), 600-608. doi: 10.1002/jcb.22185 PMID: 19459166
  205. Yin, D.; Ong, J.M.; Hu, J.; Desmond, J.C.; Kawamata, N.; Konda, B.M.; Black, K.L.; Koeffler, H.P. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo. Clin. Cancer Res., 2007, 13(3), 1045-1052. doi: 10.1158/1078-0432.CCR-06-1261 PMID: 17289901
  206. Fouladi, M.; Park, J.R.; Stewart, C.F.; Gilbertson, R.J.; Schaiquevich, P.; Sun, J.; Reid, J.M.; Ames, M.M.; Speights, R.; Ingle, A.M.; Zwiebel, J.; Blaney, S.M.; Adamson, P.C. Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children’s Oncology Group phase I consortium report. J. Clin. Oncol., 2010, 28(22), 3623-3629. doi: 10.1200/JCO.2009.25.9119 PMID: 20606092
  207. Spiller, S.E.; Ditzler, S.H.; Pullar, B.J.; Olson, J.M. Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA). J. Neurooncol., 2008, 87(2), 133-141. doi: 10.1007/s11060-007-9505-1 PMID: 18060600
  208. Furchert, S.E.; Lanvers-Kaminsky, C.; Juürgens, H.; Jung, M.; Loidl, A.; Frühwald, M.C. Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood. Int. J. Cancer, 2007, 120(8), 1787-1794. doi: 10.1002/ijc.22401 PMID: 17230517
  209. Spiller, S.E.; Ravanpay, A.C.; Hahn, A.W.; Olson, J.M. Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma. J. Neurooncol., 2006, 79(3), 259-270. doi: 10.1007/s11060-006-9142-0 PMID: 16645722
  210. Masoudi, A.; Elopre, M.; Amini, E.; Nagel, M.E.; Ater, J.L.; Gopalakrishnan, V.; Wolff, J.E. Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res., 2008, 28(4C), 2437-2442. PMID: 18751431
  211. Su, J.M.; Li, X.N.; Thompson, P.; Ou, C.N.; Ingle, A.M.; Russell, H.; Lau, C.C.; Adamson, P.C.; Blaney, S.M. Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children’s oncology group report. Clin. Cancer Res., 2011, 17(3), 589-597. doi: 10.1158/1078-0432.CCR-10-0738 PMID: 21115653
  212. Wolff, J.E.A.; Kramm, C.; Kortmann, R.D.; Pietsch, T.; Rutkowski, S.; Jorch, N.; Gnekow, A.; Driever, P.H. Valproic acid was well tolerated in heavily pretreated pediatric patients with high-grade glioma. J. Neurooncol., 2008, 90(3), 309-314. doi: 10.1007/s11060-008-9662-x PMID: 18679579
  213. Graham, C.; Tucker, C.; Creech, J.; Favours, E.; Billups, C.A.; Liu, T.; Fouladi, M.; Freeman, B.B., III; Stewart, C.F.; Houghton, P.J. Evaluation of the antitumor efficacy, pharmacokinetics, and pharmacodynamics of the histone deacetylase inhibitor depsipeptide in childhood cancer models in vivo. Clin. Cancer Res., 2006, 12(1), 223-234. doi: 10.1158/1078-0432.CCR-05-1225 PMID: 16397046
  214. Iwamoto, F.M.; Lamborn, K.R.; Robins, H.I.; Mehta, M.P.; Chang, S.M.; Butowski, N.A.; DeAngelis, L.M.; Abrey, L.E.; Zhang, W.T.; Prados, M.D.; Fine, H.A. Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro-oncol., 2010, 12(8), 855-861. doi: 10.1093/neuonc/noq025 PMID: 20200024
  215. Hdeib, A.; Sloan, A.E. Convection-enhanced delivery of 131 I-chTNT-1/B mAB for treatment of high-grade adult gliomas. Expert Opin. Biol. Ther., 2011, 11(6), 799-806. doi: 10.1517/14712598.2011.579097 PMID: 21521146
  216. Chilamakuri, R.; Agarwal, S.J.C. Dual Targeting of PI3K and HDAC by CUDC-907 inhibits pediatric neuroblastoma growth. Cancers (Basel), 2022, 14(4), 1067. doi: 10.3390/cancers14041067
  217. Corrales-Medina, F.F.; Manton, C.A.; Orlowski, R.Z.; Chandra, J.J. Efficacy of panobinostat and marizomib in acute myeloid leukemia and bortezomib-resistant models. Leuk. Res., 2015, 39(3), 371-379.
  218. Nagaraja, S.; Vitanza, N.A.; Woo, P.J.; Taylor, K.R.; Liu, F.; Zhang, L. Transcriptional dependencies in diffuse intrinsic pontine glioma. Cancer Cell, 2017, 31(5), 635-652. doi: 10.1016/j.ccell.2017.03.011
  219. Knipstein, J.; Gore, L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin. Investig. Drugs, 2011, 20(10), 1455-1467.
  220. Li, X-N.; Shu, Q.; Su, J.M-F.; Perlaky, L.; Blaney, S.M.; Lau, C.C.J. Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC. Mol. Cancer Ther., 2005, 4(12), 1912-1922.
  221. Engelhard, H.H.; Duncan, H.A.; Kim, S.; Criswell, P.S.; Van Eldik, L.J.N. Therapeutic effects of sodium butyrate on glioma cells in vitro and in the rat C6 glioma model. Neurosurgery, 2001, 48(3), 616-624. doi: 10.1097/00006123-200103000-00035
  222. Rahman, R.; Osteso-Ibanez, T.; Hirst, R.A.; Levesley, J.; Kilday, J-P.; Quinn, S. Histone deacetylase inhibition attenuates cell growth with associated telomerase inhibition in high-grade childhood brain tumor cells. Mol. Cancer Ther., 2010, 9(9), 2568-2581.
  223. Su, J.M.; Kilburn, L.B.; Mansur, D.B.; Krailo, M.; Buxton, A.; Adekunle, A.; Gajjar, A.; Adamson, P.C.; Weigel, B.; Fox, E.; Blaney, S.M.; Fouladi, M. Phase I/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: A Children’s Oncology Group report. Neuro-oncol., 2022, 24(4), 655-664. doi: 10.1093/neuonc/noab188 PMID: 34347089
  224. Agarwal, N.; McPherson, J.P.; Bailey, H.; Gupta, S.; Werner, T.L.; Reddy, G.; Bhat, G.; Bailey, E.B.; Sharma, S. A phase I clinical trial of the effect of belinostat on the pharmacokinetics and pharmacodynamics of warfarin. Cancer Chemother. Pharmacol., 2016, 77(2), 299-308. doi: 10.1007/s00280-015-2934-1 PMID: 26719074
  225. Algar, E.M.; Muscat, A.; Dagar, V.; Rickert, C.; Chow, C.W.; Biegel, J.A.; Ekert, P.G.; Saffery, R.; Craig, J.; Johnstone, R.W.; Ashley, D.M. Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors. PLoS One, 2009, 4(2), e4482. doi: 10.1371/journal.pone.0004482 PMID: 19221586
  226. Nimmervoll, B.V.; Boulos, N.; Bianski, B.; Dapper, J.; DeCuypere, M.; Shelat, A. Establishing a preclinical multidisciplinary board for brain tumors. Clin. Cancer Res., 2018, 24(7), 1654-1666.
  227. Northcott, P.A.; Jones, D.T.; Kool, M.; Robinson, G.W.; Gilbertson, R.J.; Cho, Y-J. Medulloblastomics: The end of the beginning. Nat. Rev. Cancer, 2012, 12(12), 818-834. doi: 10.1038/nrc3410
  228. Alexander, B.M.; Ba, S.; Berger, M.S.; Berry, D.A.; Cavenee, W.K.; Chang, S.M.; Cloughesy, T.F.; Jiang, T.; Khasraw, M.; Li, W.; Mittman, R.; Poste, G.H.; Wen, P.Y.; Yung, W.K.A.; Barker, A.D. Adaptive global innovative learning environment for glioblastoma: GBM AGILE. Clin. Cancer Res., 2018, 24(4), 737-743. doi: 10.1158/1078-0432.CCR-17-0764 PMID: 28814435
  229. Chow, S-C. Adaptive clinical trial design. Annu. Rev. Med., 2017, 65, 405-415.
  230. Hargrave, D.R.; Bouffet, E.; Tabori, U.; Broniscer, A.; Cohen, K.J.; Hansford, J.R.; Geoerger, B.; Hingorani, P.; Dunkel, I.J.; Russo, M.W.; Tseng, L.; Dasgupta, K.; Gasal, E.; Whitlock, J.A.; Kieran, M.W. Efficacy and safety of dabrafenib in pediatric patients with BRAF V600 mutation-positive relapsed or refractory low-grade Glioma: Results from a phase I/IIa study. Clin. Cancer Res., 2019, 25(24), 7303-7311. doi: 10.1158/1078-0432.CCR-19-2177 PMID: 31811016
  231. Nicolaides, T.; Nazemi, K.; Crawford, J.; Kilburn, L.; Minturn, J.; Gajjar, A.; Gauvain, K.; Leary, S.; Dhall, G.; Aboian, M.; Robinson, G.; Molinaro, A.; Mueller, S.; Prados, M. Pdct-19. A safety study of vemurafenib, an oral inhibitor of braf(V600e), in children with recurrent/refractory braf(V600e) mutant brain tumors: Pnoc-002. Neuro-oncol., 2017, 19(Suppl. 6), vi188. doi: 10.1093/neuonc/nox168.761
  232. Dobbins, R.; MacDonald, T.J.; Munn, D.H.; Johnson, T.S. Pediatric trial of indoximod with chemotherapy and radiation for relapsed brain tumors or newly diagnosed DIPG., , NCT04049669.
  233. Kramer, B.; Singh, R.; Wischusen, J.; Dent, R.; Rush, A.; Middlemiss, S.; Ching, Y.W.; Alexander, I.E.; McCowage, G. Clinical Trial of MGMT (P140K). Hum. Gene Ther., 2018, 29(8), 874-885. doi: 10.1089/hum.2017.235 PMID: 29385852
  234. Parasramka, S.; Talari, G.; Rosenfeld, M.; Guo, J. Procarbazine, lomustine and vincristine for recurrent high-grade glioma. Cochrane Database Syst. Rev., 2017, 7(7), CD011773.
  235. Dunsmore, K.P.; Winter, S.; Devidas, M.; Wood, B.L.; Esiashvili, N.; Eisenberg, N. COG AALL0434: A randomized trial testing nelarabine in newly diagnosed t-cell malignancy. J. Clin. Oncol., 2018, 36(15), 10500.
  236. Stein, A.; Franklin, J.L.; Chia, V.M.; Arrindell, D.; Kormany, W.; Wright, J. Benefit-risk assessment of blinatumomab in the treatment of relapsed/refractory B-cell precursor acute lymphoblastic leukemia. Drug Saf., 2019, 42(5), 587-601.
  237. Amin, N.L. Osteonecrosis and bone health in children, teenagers and young people with leukaemia. PhD thesis, University of Leeds., 2019.
  238. Blaney, S.M.; Boyett, J.; Friedman, H.; Gajjar, A.; Geyer, R.; Horowtiz, M.; Hunt, D.; Kieran, M.; Kun, L.; Packer, R.; Phillips, P.; Pollack, I.F.; Prados, M.; Heideman, R. Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001). J. Clin. Oncol., 2005, 23(3), 525-531. doi: 10.1200/JCO.2005.06.544 PMID: 15659498
  239. Doz, F.; Locatelli, F.; Baruchel, A.; Blin, N.; De Moerloose, B.; Frappaz, D. Phase I dose-escalation study of volasertib in pediatric patients with acute leukemia or advanced solid tumors. Pediatr. Blood Cancer, 2019, 66(10), e27900. doi: 10.1002/pbc.27900

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bentham Science Publishers, 2024